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Purpose
Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer sus-
ceptibility genes and may represent a more efficient and less expensive approach than 
sequential testing. We assessed the frequency of germline mutations in individuals with 
epithelial ovarian cancer (EOC), using multi-gene panels and NGS. 
Materials and Methods
Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were 
recruited consecutively, from March 2016 to December 2016. Germline DNA was sequenced
using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic 
alteration using the panel, results were cross-validated using direct sequencing. 
Results
Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight
genes, including BRCA1 (n=21), BRCA2 (n=10), BRIP1 (n=1), CHEK2 (n=2), MSH2 (n=1),
POLE (n=1), RAD51C (n=2), and RAD51D (n=2). Among 64 patients with a family history of
cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had
mutations in genes other than BRCA1/2, such as CHECK2, MSH2, POLE, and RAD51C.
Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance. 
Conclusion
Using the multi-gene panel test, we found that, of all patients included in our study, 32.5%
had germline cancer-predisposing mutations. NGS was confirmed to substantially improve
the detection rates of a wide spectrum of mutations in EOC patients compared with those
obtained with the BRCA1/2 testing alone.
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Introduction
The evaluation of germline mutations in high-penetrance
epithelial ovarian cancer (EOC) predisposition genes, specif-
ically BRCA1 and BRCA2 (BRCA1/2), has become a standard
clinical practice. Lifetime estimates of EOC risk range from
24% to 59% and 8% to 35% in BRCA1 and BRCA2 carriers, 
respectively [1-4]. Identification of BRCA1/2 mutations 
allows the application of preventive strategies, including
breast magnetic resonance imaging (MRI) screening or risk-
reducing surgeries, which can improve survival [5,6].
With the advances in the next-generation sequencing
(NGS), simultaneous sequencing of multiple cancer suscep-
tibility genes beyond BRCA has become available through
multi-gene panel testing in a less expensive and more rapid
manner, compared with that of the single-gene testing [7].
Additionally, testing multiple genes simultaneously creates
the potential for unexpected findings as well as for the iden-
tification of genetic alterations for which the clinical manage-
ment has not been established yet [7-9]. Previous investiga-
tions of germline mutations using multi-gene panel testing
of EOC patients revealed that 18%-24% of patients carry
germline mutations in BRCA1/2, BARD1, BRIP1, CHEK2,
MRE11A, MSH6, NBN, PALB2, RAD50, RAD51C, RAD51D,
or TP53 genes [7,9]. Furthermore, in one study, which 
included 127 EOC patients who previously underwent non-
informative genetic screening, nine patients (7%) were found
to have pathogenic mutations in APC, ATM, BRCA2, BRIP1,
MUTYH, and RAD51D genes [8].
However, considering the ethnicity-specific differences in
the germline mutations in cancer susceptibility genes, the 
assessment of cancer susceptibility gene variants in all ethnic
groups using clinical data is necessary. In Asians, no previ-
ous studies evaluated the frequency of germline mutations
in cancer susceptibility genes other than BRCA1/2 genes in
individuals with EOC who were referred for genetic evalua-
tion.
The primary objective of this study was to investigate the
frequency and spectrum of germline mutations in 35 cancer
susceptibility genes using multi-gene panel testing in a pop-
ulation of consecutive Korean patients with EOC.
Materials and Methods
1. Patient selection
All women with EOC admitted to Severance Hospital,
Yonsei University, South Korea, between March 2016 and 
December 2016, who consented to multi-gene panel testing
for clinical research, were included in this study. Blood sam-
ples of the participants were obtained, and the clinical and
pathologic data abstracted from medical records included
personal and family cancer histories, cancer histology, stage,
ancestry, and previous genetic test results. All ovarian can-
cers were reviewed by a gynecologic pathologist panel at the
same institute. Genetic test results obtained in this study
were considered research results and were not returned to
study participants or utilized for clinical decision making. 
2. NGS assay
Germline DNA was extracted from peripheral blood sam-
ple of the participants using the QIAamp Blood DNA mini
Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Intact DNA was quantified and adjusted
to the concentration of 5 ng/µL using a Qubit 2.0 Fluorome-
ter (Invitrogen, Waltham, MA) and the Qubit dsDNA HS
Assay Kit (Invitrogen). Precapture libraries were constructed
according to the manufacturer’s sample preparation proto-
col. Genomic DNA of each patient was fragmented to a 
median size of 300 bp. We used customized targeted capture
sequencing panel (OncoRisk, Celemics, Seoul, Korea) cover-
ing all coding sequences and intron-exon boundaries of the
coding exons of 35 cancer susceptibility genes, including
BRCA1, BRCA2, PALB2, BARD1, BRIP1, RAD51C, RAD51D,
RAD50, NBN, MRE11A, ATM, CHEK2, TP53, PTEN, APC,
BLM, BMPR1A, CDH1, CDK4, CDKN2A, EPCAM, MEN1,
MLH1, MSH2, MSH6, MUTYH, PMS2, POLE, PRSS1, RET,
SLX4, SMAD4, STK11, VLH, and WT1. DNA fragments were
end-repaired, phosphorylated, and adenylated at the 3 ends.
The index adaptors were ligated to the repaired ends, DNA
fragments were amplified, and fragments of 200 to 500 bp
were isolated. Pooled libraries were sequenced on a MiSeq
sequencer (Illumina, San Diego, CA) using the MiSeq Rea-
gent Kit v2 (300 cycles).
3. NGS data analysis 
All clinically actionable variants identified by NGS, as well
as regions that did not meet our preset NGS quality metrics,
were independently confirmed with orthogonal site-specific
Sanger sequencing. Analyzed genes were categorized 
according to the cancer type-predisposing mutations (Table 1).
4. Annotation and variant classification
Variants were described according to nomenclature rec-
ommendations of the Human Genome Variation Society
(http://www.hgvs.org/mutnomen) and further categorized
according to the American College of Medical Genetics and
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Genomics recommendations, with supporting linkage, bio-
chemical, clinical, functional, and statistical data used for
specific missense and intronic alterations [10-12]. The vari-
ants were classified into pathogenic, likely pathogenic, vari-
ant of uncertain significance (VOUS), likely benign, and
benign/polymorphism, using five-tier system following the
guidelines of the American College of Medical Genetics and
Genomics [10]. Initially, variants were filtered by their fre-
quencies in population control databases including ExAC
(nonThe Cancer Genome Atlas dataset; frequencies were
calculated according to the ethnic subgroups), ESP6500, 1000
Genomes Project, and Korean Reference Genome Database.
Variants with a minor allele frequency (MAF) greater than
5% in any of the population subgroups were classified as 
absolutely benign. Conventionally, variants with a MAF
greater than 0.5% were considered as having a strong evi-
dence for a benign variant, whereas the evidence supporting
pathogenicity was considered moderate if these variants
were shown to be absent from the general population. Fur-
thermore, literature and database search for previous reports
and functional studies was performed using Alamut Visual
2.6 software (Interactive Biosoftware, Rouen, France) and
Human Gene Mutation Database professional database.
When all in silico analyses showed consistent predictions, the
results were considered the evidence demonstrating that a
certain variant is benign or pathogenic.
5. Confirmation by other methods
We identified all small base pair variations using Sanger
sequencing on a 3730 DNA Analyzer with the BigDye Ter-
minator v3.1 Cycle Sequencing Kit (Applied Biosystems, Fos-
ter City, CA). Sequencing data were aligned against appro-
priate reference sequences and analyzed using the Sequen-
cher 5.3 software (Gene Codes Corp., Ann Arbor, MI). Chro-
mosomal copy number alterations were confirmed using the
Infinium CytoSNP 850K array (Illumina) and BlueFuse Multi
software (Illumina).  
6. Ethical statement 
This study was approved by the Institutional Review
Board of the Yonsei University College of Medicine (No. 
4-2015-0141) and performed in accordance with the ethical
standards described in the Declaration of Helsinki. The 
requirement to obtain a written informed consent was
waived by the Institutional Review Board of the Yonsei Uni-
versity College of Medicine because our study was retrospec-
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Table 1. Hereditary cancer predisposition genes included in the multi-gene panel test
Gene Breast Ovarian Colorectal Endometrial Pancreatic Gastric Prostate Other
BRCA1, BRCA2 O O - - O - O -
MLH1, MSH2, MSH6, - O O O O O - O
PMS2, EPCAM
STK11 O O O O O O - O
APC, BMPR1A, SMAD4 - - O - O O - O
MUTYH - - O - - - - O
CDKN2A, CDK4 - - - - O - - -
TP53 O O O O O O O O
PTEN O - O O - - - O
CDH1 O - O - - O - -
PALB2, ATM O - - - - - - -
CHEK2 O - O - O - O -
NBN O - - - - - O -
BARD1 O - - - - - - -
BRIP1, RAD51C, RAD51D, O O - - - - - -
RAD50, SLX4
BLM - - - - - - - O
MEN1, RET - - - - - - - O
MRE11A O - - - - - - -
POLE - - O - - - - -
PRSS1 - - - - O - - -
VHL, WT1 - - - - - - - O
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Characteristic Total Mutation BRCA1/2 Non-BRCA1/2 p-value(n=117) (n=38)a) mutation (n=31) mutation (n=8)
Age, median (range, yr) 52 (16-83) 58 (40-76) 56 (45-76) 54 (40-71) 0.360
Stage
I 25 (21.4) 3 (7.9) 1 (3.2) 2 (25.0) 0.086
II 8 (6.8) 3 (7.9) 3 (9.7) 0 (
III 51 (43.6) 21 (55.3) 18 (58.1) 4 (50.0)
IV 33 (28.2) 11 (28.9) 9 (29.0) 2 (25.0)
Histology
Serous 83 (70.9) 33 (86.8) 28 (90.3) 6 (75.0) 0.172
Mucinous 7 (6.0) 0 ( 0 ( 0 (
Endometrioid 11 (9.4) 1 (2.6) 1 (3.2) 0 (
Clear cell 10 (8.5) 1 (2.6) 0 ( 1 (12.5)
Mixed 6 (5.1) 3 (7.9) 2 (6.5) 1 (12.5)
Ancestry
Asian 116 (99.1) 38 (100) 31 (100) 8 (100) > 0.99
White/Caucasian 1 (0.9) 0 ( 0 ( 0 (
Family history of cancer 64 (54.7) 25 (65.8) 21 (67.7) 4 (50.0) 0.712
Diagnosis at less than 50 47 (40.2) 10 (26.3) 8 (25.8) 2 (25.0) 0.795
Concurrent breast cancer 7 (6.0) 6 (15.8) 6 (19.4) 0 ( 0.307
Table 2. Patient characteristics
Values are presented as number (%). a)Two mutations including BRCA1 and one non-BRCA1/2 gene were identified simul-
taneously in a patient.
Fig. 1. Multiple-gene panel testing results. In a patient, multiple mutations were concomitantly identified. EOC, epithelial
ovarian cancer; VOUS, variants of uncertain significance. a)Two mutations including BRCA1 and one non-BRCA1/2 gene
were identified simultaneously in a patient.
EOC patients (n=117)
Mutation
Patients (n=38, 32.5%)
Mutations identifieda) (n=39) 
VOUS only
Patients (n=55, 47.0%)
VOUS identified (n=145)
VOUS in 34 genes
APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, 
BRIP1, CDH1, CDH2, CDK4, CDKN2A, CHEK2,
EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, 
NBN, PALB2, PMS2, POLE, PRSS1, PRSS3, RAD50,
RAD51C, RAD51D, RET, SLX4, TP53, VHL, and WT1
Mutations in 8 genes
BRCA1, BRCA2, BRIP1, CHEK2, MSH2, 
POLE, RAD51C, and RAD51D
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tive research based on medical records, and this research pre-
sented no more than minimal risk of harm to subjects.
Results
1. Study population
In Fig. 1, the results of multi-gene panel testing are pre-
sented. Of 117 patients with EOC, 44 deleterious mutations
were identified in 38 (32.5%) women, and 55 patients (47.0%)
were revealed to carry only VOUSs in 34 genes. Multiple 
genetic mutations were concomitantly identified in a patient.
Clinical and tumor pathologic features of study participants
per state of mutation are shown in Table 2. Out of 38 patients
with pathogenic or likely pathogenic mutations, 31 had
BRCA1/2 mutation and eight were shown to carry non-
BRCA1/2 mutations. All the BRCA1/2 mutations detected in
NGS assay were also confirmed by Sanger sequencing. The
median age at diagnosis was 52 years (range, 16 to 83 years);
99.1% of the study population was Asian, and 0.9% was non-
Ashkenazi white; 71.8% of the patients had stage III or IV dis-
ease. Furthermore, 54.7% of patients reported having a
first-degree relative with cancer. In total, 64 patients (54.7%)
had a family history of cancer, and among 38 patients who
carried deleterious mutations in genes, 25 patients (65.8%)
had family history of cancer in first-degree relatives. Concur-
rent breast cancers were found in seven patients (6%), and
five of them carried BRCA1 mutation, while one carried
BRCA2. There were no significant differences in the clinico-
pathologic characteristics between patients with BRCA1/2
mutation and patients with non-BRCA1/2 mutation. Also,
Kaplan-Meier analysis showed there were no differences in
progression-free survival (p=0.567) and overall survival
(p=0.492) between the two groups (S1 Fig.).
2. Frequency and spectrum of pathogenic and likely path-
ogenic mutations
Frequency of genetic alterations, including pathogenic or
likely pathogenic mutations and VOUSs, is illustrated in 
Fig. 2. All the data with anonymized and deidentified patient
information is available in S2 Table. Among 117 patients with
EOC, 39 pathogenic or likely pathogenic mutations were
identified in 38 women (32.5%). Out of 39 germline muta-
tions detected, 31 (79.5%) were shown to be germline
BRCA1/2 mutation, 21 in BRCA1, and 10 in BRCA2. In addi-
tion, eight (6.8%) women had a total of eight deleterious 
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Fig. 2. Proportion of pathogenic or likely pathogenic mutations and variants of uncertain significance (VOUSs). (A) Multi-
gene panel test results. (B) Proportion and number of pathogenic or likely pathogenic mutations.
POLE (n=1, 3%)
MSH2 (n=1, 3%)
CHEK2 (n=1, 2%)
BRIP1 (n=1, 2%)
BRCA1 (n=21, 54%)
BRCA2 (n=10, 26%)
RAD51C 
(n=2, 5%)
RAD51D 
(n=2, 5%)
Mutation
(n=38, 32%)
VOUS only
(n=55, 47%)
None
(n=24, 21%)
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mutations in non-BRCA1/2 cancer predisposition genes 
including BRIP1 (n=1), CHEK2 (n=1), MSH2 (n=1), POLE
(n=1), RAD51C (n=2), and RAD51D (n=2). Characteristics of
patients with non-BRCA1/2 mutations are presented in 
Table 3. 
We did not find any deleterious mutations in APC, ATM,
BARD1, BLM, BMPR1A, BMPR1B, CDH1, CDH2, CDKN2A,
EPCAM, MEN1, MRE11A, MLH1, MSH6 MUTYH, NBN,
PALB2, PMS2, PRSS1, RAD50, RET, SLX4, STK11, TP53,
VHL, or WT1 genes. 
3. Frequency of VOUSs in cancer susceptibility genes  
Clinical and tumor pathologic features of study partici-
pants per state of VOUS are presented in S3 Table. Frequency
and spectrum of identified VOUSs are illustrated in Fig. 3.
At least one VOUS was identified in 78 women (66.7%), and
145 VOUSs have been identified in total. Twenty-five 
patients with VOUS also had a concomitant deleterious 
mutation. Among 54 patients (46.2%) that carried only
VOUSs, 30 patients had a family history of cancer in the first-
degree relatives. 
Discussion
To the best of our knowledge, this is the first study that 
included consecutively enrolled EOC patients of the Asian
ethnicity, and retrospectively examined the frequency and
spectrum of germline mutations in BRCA1/2 and other cancer
predisposition genes. Among 117 patients, we found that 38
patients (32.5%) carried pathogenic and likely pathogenic
mutations, while eight patients (6.8%) were shown to have
mutations in non-BRCA1/2 cancer predisposition genes, 
including BRIP1, CHEK2, MSH2, POLE, RAD51C, and
RAD51D. 
A large-scale study presented spectrum of germline 
mutations of ovarian cancer patients, whose ethnicities were
predominantly non-Hispanic whites (87.4%) [9]. The research
reported germline mutations in BRIP1 (1.4%), RAD51C
(0.6%), RAD51D (0.6%), MLH1 (0.01%), and CHEK2 (0.06%),
which also found in our study. [9] However, considering the
extensive gap between the numbers of subjects (1,915 
patients vs. 117 patients), a direct comparison with our 
results is not acceptable. NGS panel test for patients with
EOC began to be covered by National Health Insurance from
March 2017, systematic gathering and analysis of the pro-
duced data from ovarian cancer patients with Korean ethnic-
ity are required to compare with the data from another
ethnicity.
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RAD51C and RAD51D are known to correlate with an 
increased risk of EOC due to their involvement in the Fan-
coni-BRCA pathway [13,14]. RAD51C mutations are found
in 1% of unselected EOC patients and confer an overall life-
time EOC risk of about 9% at an average onset age of 60 years
[14]. A previous population-based case-control study demon-
strated that RAD51C and RAD51D represent moderate EOC
susceptibility genes, and 18% of EOCs (more frequently in
high-grade serous type) carrying RAD51C and RAD51D
mutations developed at age 50 or younger. If this risk esti-
mate is confirmed, risk-reducing salpingo-oophorectomy
may be a beneficial option for premenopausal women [15].
We identified four participants with pathogenic or likely
pathogenic mutations, including RAD51C c.597_603del-
CACTCTT (p.Phe199LeufsTer38), RAD51D c.270_271dupTA
(p.Lys91IlefsTer13), and RAD51D c.904-2A>T.
BRCA1-interacting protein C-terminal helicase 1 (BRIP1)
is involved in the BRCA-Fanconi anemia pathways, and it
was identified as a moderate-penetrance gene, conferring an
increased risk for EOC, with 6-8-fold increased EOC risk and
10%-15% lifetime risk [16,17]. Another report demonstrated
that BRIP1 mutations were found in 1.4% of EOC patients,
and they were shown to be associated with a moderate 
increase in EOC risk. These data have clinical implications
for the development of preventive strategies for the BRIP1
mutation carriers [18]. We identified one patient in our study
as a carrier of a deleterious mutation, BRIP1 c.1776G>A
(p.Trp592Ter), who has no family history of cancer in the
first-degree relatives. 
Cell-cycle checkpoint kinase 2 (CHEK2) plays a role in cell-
cycle arrest and DNA repair and its mutations contribute to
the development of hereditary and sporadic cancers [19].
One meta-analysis showed that CHEK2 1100delC increases
the lifetime risk 3-5 folds, with a 37% increase in the cumu-
lative risk of breast cancer by the age of 70 [20]. A previous
study examining Asian population reported that CHEK2
c.1111C>T (p.His371Tyr, rs531398630) was detected in famil-
ial and unselected breast cancer cases and controls, with
4.24% (5/118), 1.76% (16/909), and 0.73% (9/1228), respec-
tively  [21]. In this study, we identified two EOC patients
(age, 31 and 40 years) with pathogenic mutation, CHEK2
c.1111C>T (p.His371Tyr) and c.1555C>T (p.Arg519Ter), and
a family history of hematologic cancer and colon cancer in
the first-degree relatives, respectively. The patients were 
referred to the department of breast surgery, and followed
up with regular surveillance using breast MRI. 
The benefit of genetic testing for BRCA1/2 mutations is
well established. In addition to cancer prevention strategies
such as risk-reducing surgery, BRCA-associated cancers were
confirmed to show a better response to therapies such as
poly(ADP) ribose polymerase (PARP) inhibitors and plat-
inum agents than sporadic cancers [22,23]. Considering the
role of BRIP1, CHEK2, RAD51C, and RAD51D in the BRCA
pathway responsible for DNA repair, EOCs in patients with
mutations in BRIP1, CHEK2, RAD51C, or RAD51D may rep-
resent potential targets for PARP1 inhibitors, similar to the
BRCA1/2 mutation carriers.
The usefulness of multi-gene panel testing aimed at the 
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detection of germline mutations would be more beneficial
for the familial surveillance and risk-reduction strategies,
rather than the application of a targeted therapy, such as
PARP1 inhibition therapy. Currently, the National Compre-
hensive Cancer Network (NCCN) guidelines recommend
risk-reducing salpingo-oophorectomy when known muta-
tions in the EOC-associated genes (BRCA1, BRCA2, RAD51C,
RAD51D, BRIP1, MSH2, MLH1, MSH6, and PMS2) are 
detected [24]. Additionally, risk-reducing mastectomy is rec-
ommended when known breast cancer–associated gene
(BRCA1, BRCA2, CDH1, PTEN, TP53, and PALB2) mutations
are identified. Furthermore, the mutations in ATM, BRCA1,
BRCA2, CDH1, CHEK2, PLAB2, PTEN, STK11, and TP53 sug-
gest that the subsequent screening using breast MRI may be
indicated [24].
Mutations in the mismatch repair genes (MLH1, MSH2,
MSH6, PMS2, and EPCAM), which cause Lynch syndrome,
are often considered the major causes of hereditary EOC, in
addition to BRCA1 and BRCA2 mutations [25]. The identifi-
cation of these mutations may allow an improved surveil-
lance, leading to the identification of colorectal, endometrial,
ovarian, and other cancers in patients with EOC and their
relatives [26]. An MSH2 mutation, c.1321dupA (p.Thr441As-
nfsTer2), was detected in our study, and the patients had sig-
moid colon cancer concomitantly with the family history of
stomach cancer. Further large population-based studies are
required to establish the frequency of deleterious mutations
in these genes.
We detected a non-hereditary breast-ovarian cancer syn-
drome related gene, POLE. The POLE gene mutation was 
reported as a risk factor for the early onset mismatch repair-
deficient colorectal cancer [27]. According to the NCCN
guidelines, enhanced colorectal cancer screening is recom-
mended in patients with a germline mutation in POLE gene.
According to the data collected in this study, 78 patients
(66.7%) were shown to have 145 VOUSs in 34 genes (Fig. 3).
Approximately one-third of patients had at least one VOUS,
as previously reported in other studies evaluating NGS pan-
els [4,26]. Most of them will eventually be categorized, most
likely as benign, but some will be categorized as deleterious
[12,28]. Until their significance is fully understood, VOUSs
should not be used for making clinical decisions. 
The application of multi-gene panel testing in the evalua-
tion of cancer susceptibility genes has been rapidly increas-
ing in clinical practice. These multi-gene panel tests can be
used for the analysis of not only high-penetrance genes with
established clinical utility, but also genes for which clinical
validity or significance is currently less evident. The appro-
priate interpretation of results is important for the develop-
ment and recommendation of effective strategies for risk
management, which may be challenging for clinicians, who
often lack genetic training, and for their patients, who should
undergo the screening and prevention strategy decision-
making process. 
In conclusion, here we presented germline mutation data
obtained from unselected EOC patients of Asian ethnicity.
Overall, 38 out of 117 EOC patients (32.5%) were shown to
have 39 germline mutations in eight genes (BRCA1, BRCA2,
BRIP1, CHEK2, MSH2, POLE, RAD51C, and RAD51D). We
identified non-BRCA1/2 cancer predisposition genes muta-
tion in eight out of 117 patients (6.8%). NGS has a potential
to substantially improve the detection rates of a wide spec-
trum of mutations in ovarian cancer patients compared with
the BRCA1/2 testing alone.
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